(ICD‐O‐3 C61) (FIG. 477, SEE ALSO FIG . 524)



PROSTATE (ICD‐O‐3 C61) (FIG. 477, SEE ALSO FIG . 524)


Rules for Classification


The classification applies only to adenocarcinomas. Transitional cell carcinoma of the prostate is classified as a urethral tumour (see Urethra). There should be histological confirmation of the disease.

Schematic illustration of Prostate.

Fig. 477


Regional Lymph Nodes (Fig. 478)


The regional lymph nodes are the nodes of the true pelvis, which essentially are the pelvic nodes below the bifurcation of the common iliac arteries. Laterality does not affect the N classification.

Schematic illustration of The regional lymph nodes are the nodes of the true pelvis, which essentially are the pelvic
nodes below the bifurcation of the common iliac arteries.

Fig. 478


TNM Clinical Classification


T – Primary Tumour













































TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Clinically inapparent tumour that is not palpable (Fig. 479)

T1a Tumour incidental histological finding in 5% or less of tissue resected

T1b Tumour incidental histological finding in more than 5% of tissue resected

T1c Tumour identified by needle biopsy (e.g., because of elevated PSA)
T2 Tumour that is palpable and confined within prostate1

T2a Tumour involves one half of one lobe or less (Fig. 480)

T2b Tumour involves more than half of one lobe, but not both lobes (Fig. 480)

T2c Tumour involves both lobes (Fig. 481)
T3 Tumour extends through the prostatic capsule2

T3a Extraprostatic extension (unilateral or bilateral) including microscopic bladder neck involvement (Figs. 482, 483)

T3b Tumour invades seminal vesicle(s) (Fig. 484)
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall (Figs. 485, 486)

Notes


1 Tumour found in one or both lobes by needle biopsy, but not palpable, is classified as T1c.


2 Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified as T3, but as T2.

Schematic illustration of Clinically inapparent tumour that is not palpable.

Fig. 479

Schematic illustration of tumour involves one half of one lobe or less.

Fig. 480

Schematic illustration of tumour involves both lobes.

Fig. 481

Schematic illustration of Extraprostatic extension (unilateral or bilateral) including microscopic bladder neck involvement.

Fig. 482

Schematic illustration of Extraprostatic extension (unilateral or bilateral) including microscopic bladder neck involvement.

Fig. 483

Schematic illustration of tumour invades seminal vesicle(s).

Fig. 484

Schematic illustration of tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles, and pelvic wall.

Fig. 485

Schematic illustration of tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles, and pelvic wall.

Fig. 486


N – Regional Lymph Nodes












NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis (Figs. 487, 488)

Note
Metastasis no larger than 0.2 cm can be designated pN1mi.

Schematic illustration of Regional lymph node metastasis.

Fig. 487

Schematic illustration of Regional lymph node metastasis.

Fig. 488


M – Distant Metastasis*


















M0 No distant metastasis
M1 Distant metastasis

M1a Non‐regional lymph node(s)

M1b Bone(s)

M1c Other site(s)

Note


* When more than one site of metastasis is present, the most advanced category is used. pM1c is the most advanced category.


pTNM Pathological Classification


The pT and pN categories correspond to the T and N categories.


However, there is no pT1 category because there is insufficient tissue to assess the highest pT category. There are no subcategories of pT2.






pM1 Distant metastasis microscopically confirmed

Note
pM0 and pMX are not valid categories.


Summary

Tags:
Dec 15, 2022 | Posted by in ONCOLOGY | Comments Off on (ICD‐O‐3 C61) (FIG. 477, SEE ALSO FIG . 524)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access